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To establish whether the combination of anti-resorptive therapy with mechanical loading has a negative,
additive or synergistic effect on bone structure, we assessed the separate and combined effects of risedronate
and non-invasive dynamic loading on trabecular and cortical bone. Seventeen-week-old female C57BL/6 mice
were given daily subcutaneous injections of vehicle (n=20) or risedronate at a dose of 0.15, 1.5, 15 or 150 μg/
kg/day (n=10 in each) for 17 days. From the fourth day of treatment, the right tibiae were subjected to a
single period of axial loading (40 cycles/day) for three alternate days per week for two weeks. The left tibiae
were used as internal controls. Trabecular and cortical sites in the tibiae were analyzed by high-resolution
micro-computed tomography and imaging of ﬂuorochrome labels. In the non-loaded tibiae, treatment with
the higher doses of risedronate at 15 or 150 μg/kg/day resulted in higher trabecular bone volume and
trabecular number than in vehicle-treated controls, whereas such treatment was associated with no
differences in cortical bone volume at any dose. In the loaded tibiae, loading induced increases in trabecular
and cortical bone volume compared with contra-lateral controls primarily through increased trabecular
thickness and periosteal expansion, respectively, independently of risedronate treatment. In conclusion, the
response to mechanical loading in both trabecular and cortical bone in mice is therefore not impaired by
short-term treatment with risedronate, even over a 1000-fold dose range. In considering the optimization of
treatments for osteoporosis, it is reassuring that anti-resorptive therapy and mechanical loading can exert
independent beneﬁcial effects.
This article is part of a Special Issue entitled Bisphosphonates.
© 2011 Elsevier Inc.
Introduction
Bisphosphonates play a central role in the management of osteopo-
rosis [1–3]. Their major mechanism of action is to suppress osteoclast
function and survival [4,5]. Due to thenormal couplingof bone resorption
to formation, one of their effects is to lower bone turnover [6]. Some of
these drugs have also recently been demonstrated to protect osteocytes
from apoptosis in vivo [7,8]. In contrast to the anti-resorptive effects of
bisphosphonates, mechanical loading is the predominant functional
osteogenic factor responsible for maintaining structurally appropriate
levels of bone mass in adults [9,10].
By suppressing bone resorption, bisphosphonates effectively slow
the decline in bone mass due to any cause including decreased
mechanical loading [11–15]. The question remains as to their effect on
the (re)modeling associatedwith a net osteogenic stimulus such as that
derived from a therapeutic regimen of exercise. Some pilot clinical
reports have shown an additive effect of bisphosphonates and exercise
on areal bonemineral density [16,17], but other trials failed to ﬁnd such
an additive effect [18–20]. In experiments involving treadmill exercise
in ovariectomized rats, the combination of etidronate, alendronate or
risedronate treatment with exercise had additive or synergistic effects
on bones [21–23], whereas zoledronic acid and exercise did not show
either effect [24].
Since exercisewould induce signiﬁcant changes in cardio-pulmonary
and nervous systems as well as skeletal muscle, the effect of combining
bisphosphonateswith localmechanical stimulationhasbeen studied in a
variety of rodent loading models. Again, however, the results are not
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consistent [25–28]. The effect of clodronate on periosteal appositionwas
increased when combined with mechanical loading in the rat tibia [25],
whereas a recent study suggested that zoledronic acid impaired cortical
bone's response to loading in the mouse tibia [28]. In contrast,
alendronate, risedronate and zoledronic acid at clinical doses did not
inﬂuence periosteal expansion induced by loading in the rat ulna [27].
Only one study investigated the effect of combining a bisphosphonate
with loading in trabecular bone and showed that pamidronate did not
change osteogenesis caused by invasive loading in the rat tail [26].
Among the currently available bisphosphonates with different
mineral binding and biochemical actions, risedronate has a compar-
atively lower afﬁnity for bone mineral [29,30], whichmay facilitate its
access to the mechano-responsive cells of the osteocytic lacunar
network [31]. Importantly, risedronate has a relatively potent action
on the appendicular skeleton [4,32]. In the present study, we assessed
the separate and combined effects of various doses of risedronate with
external mechanical loading on trabecular and cortical bone, by using
the non-invasive mouse tibia axial loading model [33,34]. This
approach has the advantage that it allows examination of the effect
of local mechanical stimulation, distinct from that of exercise, in both
trabecular and cortical bone compartments.
Materials and methods
Animals
Virgin, female C57BL/6 mice were purchased from Charles River
Laboratories Inc. (Margate, UK) at 7 weeks of age, and housed in
sterilized polypropylene cages (n=5 per cage) with free access to
water and a maintenance diet containing 0.73% calcium, 0.52%
phosphorus, and 3.5 IU/g vitamin D (RM1; Special Diet Services Ltd.,
Witham, UK) in a 12-hour light/dark cycle, with room temperature at
21±2 °C. All procedures complied with the UK Animals (Scientiﬁc
Procedures) Act 1986 and were reviewed and approved by the ethics
committee of the Royal Veterinary College (London, UK).
Experimental design
At 17 weeks of age, 60 mice were divided into ﬁve body weight-
matched groups and treated with daily subcutaneous injections of
vehicle (saline; n=20) or risedronate (Procter & Gamble Pharmaceu-
ticals, Inc., Mason, Ohio, USA) at a dose of 0.15 (n=10), 1.5 (n=10), 15
(n=10) or 150 (n=10) μg/kg/day for 17 days (days 1–17). 1.5 μg/kg/
day is a dose equivalent to that used clinically in osteoporosis patients
based on a mg/kg basis and on its known low intestinal absorption.
During this treatment, the right tibiae were subjected to external
loading under isoﬂurane-induced anesthesia for three alternate days
per week (approximately 7 min/day) on days 4, 6, 8, 11, 13 and 15.
Normal activity within the cages was allowed. The non-loaded contra-
lateral (left) boneswereused as internal controls, ashas previously been
validated in the model used in the present study [34] and conﬁrmed by
others in the rat ulna axial loading model [35]. High doses of calcein
(50 mg/kg; Sigma Chemical Co., St. Louis, Missouri, USA) and alizarin
(50 mg/kg; Sigma Chemical Co.) were injected intraperitoneally on the
ﬁrst and last days of loading (days 4 and15), respectively. At 19 weeksof
age (day 18), the mice were euthanized and their tibiae were collected
for analysis. Body weight was measured before (day 1) and after
(day 18) these treatments. Although it could have been potentially
interesting to use ovariectomised animals [36,37], we chose to simplify
the experimental design and to study a full dose response to risedronate
in intact animals.
In vivo external mechanical loading
The apparatus and protocol for non-invasively loading the mouse
tibia have been reported previously [33,34,37–39]. In brief, the ﬂexed
knee and ankle joints are positioned in concave cups; the upper cup,
into which the knee is positioned, is attached to the actuator arm of a
servo-hydraulic loading machine (Model HC10; Zwick Testing
Machines Ltd., Leominster, UK) and the lower cup to a dynamic load
cell. The tibia is held in place by a low level of continuous static “pre-
load”, onto which higher levels of intermittent “dynamic” load are
superimposed. In the present study, 0.5 N was used as the static “pre-
load” which was held for approximately 7 min. The 11.5 N of
“dynamic” load was superimposed onto the 0.5 N static “pre-load”
in a series of 40 trapezoidal-shaped pulses (0.025 s loading, 0.050 s
hold at 12.0 N and 0.025 s unloading) with a 10 s rest interval
between each pulse. Strain gages attached ex vivo to the proximal
tibial shaft of similar 17-week-old female C57BL/6 mice showed that a
peak load of 12.0 N engendered approximately 1200 microstrain in
that region [38].
High-resolution micro-computed tomography (μCT) analysis
The tibiae were stored in 70% ethanol and scanned by μCT
(SkyScan 1172; SkyScan, Kontich, Belgium)with a pixel size of 4.8 μm.
The images of the bones were reconstructed using SkyScan software.
As shown in Fig. 1, three-dimensional structural analyses were
performed using SkyScan software for trabecular bone (secondary
spongiosa; 0.25–0.75 mmdistal to the growth plate) and cortical bone
(0.5 mm long section at 37% of the bone's length from its proximal
end). The parameters evaluated included bone volume/tissue volume
(BV/TV), trabecular number and trabecular thickness in the trabecular
region, and bone volume, periosteally enclosed volume andmedullary
volume in the cortical region. Since it has previously been shown that
the primary effect of the present short-term loading model is
increased osteogenesis [34,40], high-resolution μCT was selected to
quantify functional adaptation. This method enables us to analyze
precisely comparable sites of the loaded and contra-lateral control
tibiae because the effects of loading are site-speciﬁc and the mouse
bone is small.
Calcein and alizarin labels imaging by confocal microscopy
After scanning by μCT, the bones were dehydrated and embedded in
methyl methacrylate as previously described [34]. Transverse segments
Fig. 1. Direction of mechanical loading in the mouse tibia and transverse μCT images at
the trabecular (0.25–0.75 mm distal to the growth plate) and cortical (0.5 mm long
section at 37% of the bone's length from its proximal end) sites analyzed.
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were obtained by cutting with an annular diamond saw. Images of
calcein and alizarin labeled bone sections were visualized using the
argon 488 nm laser and HeNe 543 nm laser, respectively, of a confocal
laser scanning microscope (LSM 510; Carl Zeiss MicroImaging GmbH,
Jena, Germany) at similar regions as the μCT analysis.
Statistical analysis
All data are shown as mean±SE. Body weight and lengths of the left
control and right loaded tibiae were compared by one-way ANOVA.
Mixed model analysis was performed on the six μCT parameters
(trabecular BV/TV, trabecular number, trabecular thickness, cortical
bone volume, periosteally enclosed volume and medullary volume).
The model ﬁxed effects were risedronate treatment (0, 0.15, 1.5, 15,
150 μg/kg/day) andmechanical loading (yes, no).Animal ID (n=60)was
included as a random variable to account for pairs of left and right tibiae
belonging to the samemouse. Final body weight was included as a ﬁxed
covariate due to its inﬂuence on bone size (signiﬁcant correlations
between body weight and cortical μCT parameters of the left tibiae were
conﬁrmed in vehicle-treated mice). Post-hoc comparison following
mixed model analysis was carried out using Bonferroni adjustment.
Statistical analysiswas performedusing SPSS forWindows (version 17.0;
SPSS Inc., Chicago, USA) and pb0.05 was considered to be signiﬁcant.
Results
Initial and ﬁnal body weight and longitudinal lengths of the left
control and right loaded tibiae are shown in Table 1. There were no
signiﬁcant differences between the body weights or bone lengths of
mice treated with vehicle or risedronate at any dose.
Effects of risedronate alone
In trabecular bone, treatment with risedronate at a dose of 15 or
150 μg/kg/day resulted in a signiﬁcantly higher BV/TV of the left non-
loaded tibiae than in vehicle-treated controls (Table 2, Fig. 2). This
increase was primarily associated with higher trabecular number. In
cortical bone, there were no signiﬁcant differences in bone volume
between vehicle-treated and risedronate-treated animals at any dose.
A dose of 0.15 μg/kg/day induced a lower medullary volume than in
vehicle-treated controls, while at a dose of 1.5 μg/kg/day there was a
slightly lower periosteally enclosed volume (Table 2, Fig. 2).
Effects of mechanical loading alone
As has been shown previously [34,37,38], mechanical loading
signiﬁcantly increased both trabecular BV/TV and cortical bone volume
(Table 2, Fig. 2). The former effect was primarily due to an increase in
trabecular thickness, while the latter response was mainly associated
with an increase in periosteally enclosed volume.
Combined effects of risedronate and mechanical loading
Mechanical loading-related increases in trabecular BV/TV and
cortical bone volume, as assessed by the difference between the right
loaded tibiae and their contra-lateral non-loaded controls, were not
signiﬁcantly inﬂuenced by treatment with risedronate, even when
given at a high dose (15 or 150 μg/kg/day) (Figs. 3 and 4). Consistent
with previous reports [34,40], the ﬂuorochrome-labeled images
supported the inference that such loading-related bone gain was
primarily associated with increased osteogenesis (Fig. 5). The additive
effect of risedronate and loading on trabecular BV/TV was found at a
Table 1
Body weight and longitudinal lengths of the left control and right loaded tibiae in mice
treated with vehicle or risedronate at a dose of 0.15, 1.5, 15 or 150 μg/kg/day.
Dose of risedronate
(μg/kg/day)
0
(n=20)
0.15
(n=10)
1.5
(n=10)
15
(n=10)
150
(n=10)
Body weight
Initial (g) 23.2±0.3 23.4±0.4 23.1±0.5 23.3±0.6 23.0±0.4
Final (g) 22.6±0.2 22.9±0.4 22.1±0.4 22.5±0.6 22.5±0.5
Length of the tibia
Left control (mm) 18.0±0.1 18.0±0.1 17.9±0.1 18.0±0.1 18.0±0.1
Right loaded (mm) 18.1±0.1 18.0±0.1 18.0±0.1 18.0±0.1 18.0±0.1
Mean±SE. No signiﬁcant differences between vehicle and risedronate at a dose of 0.15,
1.5, 15 or 150 μg/kg/day by one-way ANOVA.
Table 2
Trabecular and cortical μCT parameters in the left control and right loaded tibiae in mice treated with vehicle or risedronate at a dose of 0.15, 1.5, 15 or 150 μg/kg/day.
Dose of risedronate
(μg/kg/day)
0
(n=20)
0.15
(n=10)
1.5
(n=10)
15
(n=10)
150
(n=10)
p valuea
Risedronate Loading Interaction
Trabecular bone
Bone volume/tissue volume
Left control (%) 16.6±0.3 17.1±0.4 17.7±0.3 20.9±0.6 21.3±0.4 b0.001 b0.001 0.655
Right loaded (%) 22.7±0.5 22.6±0.5 23.2±0.6 26.4±0.7 27.7±0.8
Trabecular number
Left control (mm−1) 3.02±0.05 3.07±0.08 3.26±0.06 3.66±0.10 3.60±0.08 b0.001 b0.001 0.697
Right loaded (mm−1) 3.38±0.05 3.40±0.10 3.53±0.08 4.03±0.10 4.04±0.13
Trabecular thickness
Left control (μm) 55.1±0.5 55.7±0.8 54.4±0.6 57.3±0.8 59.2±0.9 0.009 b0.001 0.011
Right loaded (μm) 67.1±0.6 66.5±0.9 65.8±1.0 65.5±0.8 68.6±1.1
Cortical bone
Bone volume
Left control (mm3) 0.380±0.003 0.383±0.003 0.366±0.005 0.377±0.007 0.372±0.007 0.815 b0.001 0.725
Right loaded (mm3) 0.481±0.006 0.479±0.006 0.476±0.008 0.479±0.009 0.481±0.007
Periosteally enclosed volume
Left control (mm3) 0.627±0.005 0.614±0.006 0.594±0.008 0.611±0.011 0.607±0.012 0.111 b0.001 0.243
Right loaded (mm3) 0.717±0.005 0.713±0.008 0.709±0.006 0.704±0.010 0.709±0.007
Medullary volume
Left control (mm3) 0.247±0.003 0.231±0.004 0.228±0.005 0.234±0.006 0.236±0.007 0.096 0.085 0.030
Right loaded (mm3) 0.237±0.004 0.234±0.006 0.234±0.005 0.226±0.007 0.228±0.005
Mean±SE.
a Mixed model analysis including body weight.
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dose of 15 or 150 μg/kg/day (Table 2, Fig. 2), while there was no
synergistic effect of risedronate and loading on trabecular or cortical
bone at any dose (Fig. 3). A slight reduction in the loading-related
increase in trabecular thickness was observed with high doses of
risedronate, but this only reached statistical signiﬁcance at a dose of
15 μg/kg/day (Fig. 3).
Fig. 2. Relative valuesof trabecular andcorticalμCTparameters of the left control and right loaded tibiae inmice treatedwith vehicle or risedronate at adoseof0.15, 1.5, 15or 150 μg/kg/day
compared to the left control tibiae in vehicle-treated mice. Values were obtained from mixed model analysis including body weight and are presented as mean±SE (n=20 in vehicle
treatment and n=10 in risedronate treatments). #pb0.05 versus left control tibiae in vehicle-treated mice and *pb0.05 versus left control tibiae in each treatment with vehicle or
risedronate by mixed model analysis followed by Bonferroni adjustment.
Fig. 3. Loading-related changes ([right loaded− left control] / left control) in trabecular and cortical μCT parameters in mice treated with vehicle or risedronate at a dose of 0.15, 1.5,
15 or 150 μg/kg/day. Values were obtained frommixed model analysis including body weight and are presented as mean±SE (n=20 in vehicle treatment and n=10 in risedronate
treatments). *pb0.05 by mixed model analysis followed by Bonferroni adjustment.
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Discussion
In the present study, vehicle or risedronate at various doses was
administered to 17–19 week old female C57BL/6 mice and changes in
the structure of the tibiae three-dimensionally analyzed by high-
resolution μCT. Although the treatment period was short, high doses of
risedronate (15 and 150 μg/kg/day) resulted in higher trabecular BV/TV
and trabecular number. Thiswasexpected as it has been established that
treatment with bisphosphonates induces higher trabecular bone mass
by suppressing bone resorption especially during the growing period
[41]. In contrast, no signiﬁcant changes in cortical bone volume were
detected with risedronate treatment at any dose, while a low dose of
risedronate (1.5 μg/kg/day) resulted in slightly lower periosteally
enclosed volume. Some previous studies also found that risedronate
treatment suppressed periosteal bone formation in intact mice [42] and
rats [43], but no signiﬁcant effects of risedronate on periosteal
apposition were detected in skeletally mature ovariectomized rats
[27,44] and dogs [45,46]. Taken together, these studies suggest that
when the skeleton is no longer growing risedronate would have a
negligible effect on the periosteal surface.
As validated previously [34], we assessed the effects of loading by
comparing the architecture of the tibiae on one side, which received no
artiﬁcial loading, with that on the contra-lateral side which was
subjected to a regimen of non-invasive, dynamic axial loading sufﬁcient
to engender an osteogenic response. Consistent with previous studies
[34,37,38], mechanical loading produced increases in both trabecular
and cortical bone mass in all loaded limbs, primarily by increased
trabecular thickness and periosteal expansion, respectively. Such
loading-related bone gain was not reduced by treatment with
risedronate, even when given at a very high dose (150 μg/kg/day). As
a result, the effect of high-dose (15 or 150 μg/kg/day) risedronate and
loading on bone mass was additive in the trabecular region. There was
no synergistic effect of risedronate and loading on either trabecular or
cortical bone at any dose. Although the loading-related increase in
trabecular thicknesswasmarginally reduced by risedronate at a dose of
15 μg/kg/day, this could be due to lowermechanical strains engendered
resulting from the higher trabecular bone mass by the risedronate
treatment.
These results are consistent with previous histomorphometric
ﬁndings in the rat showing that the osteogenic response to mechanical
stimulation is not altered by bisphosphonates [26,27]. In the ﬁrst of
these studies [26], the tail vertebrae were invasively loaded in the
presence or absence of pamidronate and new bone formation induced
by loading in the trabecular region was independent of bisphosphonate
Fig. 4. Representative transverse μCT images of the left control and right loaded trabecular (0.25 mm distal to the growth plate) and cortical (37% of the bone's length from its
proximal end) bone in the tibiae of mice treated with vehicle or risedronate at a dose of 15 or 150 μg/kg/day.
Fig. 5. Representative transverse ﬂuorochrome-labeled images of the left control and right loaded trabecular (approximately 0.25 mm distal to the growth plate) and cortical
(approximately 37% of the bone's length from its proximal end) bone in the tibiae of mice treated with vehicle or risedronate at a dose of 15 μg/kg/day. Green: calcein label injected
on the ﬁrst day of loading (day 4). Red: alizarin label injected on the last day of loading (day 15).
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treatment. In the second [27], the effect of alendronate, risedronate and
zoledronic acidat clinical doseson load-induced corticalmodeling in the
rat ulna was investigated following ovariectomy and none of these
bisphosphonates signiﬁcantly inhibited periosteal apposition. In con-
trast, a recent experiment using the mouse tibia suggested that there
was a negative interaction between zoledronic acid and mechanical
loading in cortical bone [28]. However, this could be associated with
lower mechanical strains engendered resulting from the increased
cortical bone mass by the zoledronic acid treatment.
It remains to be determinedwhether other anabolic therapies besides
mechanical loading, when used in conjunction with an anti-resorptive
agent, have a negative, additive or synergistic effect on the skeleton.
Clinical evidence has shown that there can be a negative interaction
between alendronate and intermittent parathyroid hormone, the only
anabolic drug currently licensed for osteoporosis treatment [47,48]. This
interaction seems to be less for risedronate than alendronate [49,50]. On
the other hand, mechanical loading in rodents has been shown to
suppress sclerostin expression in osteocytes [39,51], and sclerostin
neutralizing monoclonal antibody also increases bone formation inde-
pendently of bone resorption in humans as well as rats [52,53]. Further
elucidation of the osteogenic pathways induced by mechanical loading
will therefore offer the potential for developing potent anabolic
approaches which can act independently of bone resorption.
In conclusion, mechanical loading-related increases in both trabec-
ular and cortical bone mass are not reduced by even high doses of
risedronate in almost skeletally mature female mice. This experimental
evidence suggests that osteogenic exercise canhave beneﬁcial effects on
bone health independently of those derived from the anti-resorptive
effects of bisphosphonates in patients with osteoporosis.
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